S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY. (23rd June 2022) - Passamonti, F.; Foran, J.; Tandra, A.; De Stefano, V.; Laura Fox, M.; Mattour, A.; McMullin, M. F.; Perkins, A. C.; Rodriguez-Macías, G.; Sibai, H.; Qin, Q.; Potluri, J.; et al.